Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results, Beats Expectations By $0.50 EPS

Seres Therapeutics (NASDAQ:MCRB) posted its quarterly earnings data on Thursday. The biotechnology company reported ($1.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.39) by $0.50, Zacks reports. The firm had revenue of $0.44 million during the quarter.

Seres Therapeutics Price Performance

MCRB stock traded down $0.28 on Friday, hitting $8.78. 3,643 shares of the company were exchanged, compared to its average volume of 69,579. The stock has a market capitalization of $79.41 million, a price-to-earnings ratio of -2.46 and a beta of 0.31. Seres Therapeutics has a twelve month low of $6.53 and a twelve month high of $29.98. The business’s fifty day moving average is $12.47 and its two-hundred day moving average is $15.87.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MCRB. Weiss Ratings restated a “sell (d)” rating on shares of Seres Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $14.33.

Institutional Investors Weigh In On Seres Therapeutics

A number of large investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new position in Seres Therapeutics during the 2nd quarter worth approximately $1,016,000. Invesco Ltd. grew its position in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 89,995 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Seres Therapeutics during the third quarter valued at approximately $557,000. Goldman Sachs Group Inc. lifted its position in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 21,679 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Seres Therapeutics by 6.8% during the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after purchasing an additional 19,793 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.